Moreover, we showed that Smad4 was a direct target of miR-431, and inhibition of Smad4 protected against synaptic deficits in APP/PS1 mice, which suggested that miR-431/Smad4 might act as a potential therapeutic target for AD diagnosis and treatment. Here, APP is linked to Alzheimer disease.